{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=98",
    "query": {
      "condition": "Lymphoid",
      "page": 98
    },
    "page_size": 10
  },
  "pagination": {
    "page": 98,
    "page_size": 10,
    "total_count": 3083,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=99&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=97&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T20:12:19.359Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00368355",
      "title": "T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non Hodgkins Lymphoma",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Hemophagocytic Lymphohistiocytosis (HLH)",
        "Familial Hemophagocytic Lymphohistiocytosis (FLH)",
        "Viral-associated Hemophagocytic Syndrome (VAHS)",
        "X-linked Lymphoproliferative Disease (XLP)"
      ],
      "interventions": [
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Campath-1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2000-04",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368355"
    },
    {
      "nct_id": "NCT01564784",
      "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "inotuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "FLAG (fludarabine, cytarabine and G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "HIDAC (high dose cytarabine)",
          "type": "DRUG"
        },
        {
          "name": "cytarabine and mitoxantrone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2012-08-02",
      "completion_date": "2017-01-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 96,
      "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 39 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01564784"
    },
    {
      "nct_id": "NCT00849147",
      "title": "Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
        "Leukemia, Myeloid, Acute",
        "Burkitt Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Haploidentical Bone Marrow Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GVHD prophylaxis",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": 55,
      "start_date": "2008-10",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 17,
      "location_summary": "Duarte, California • La Jolla, California • Gainesville, Florida + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849147"
    },
    {
      "nct_id": "NCT02890758",
      "title": "Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Myeloproliferative Syndromes",
        "Plasma Cell Myeloma",
        "Colon Carcinoma",
        "Adenocarcinoma of Rectum",
        "Soft Tissue Sarcoma",
        "Ewing's Sarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Natural Killer (NK) Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Brenda Cooper, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-05-22",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890758"
    },
    {
      "nct_id": "NCT00501826",
      "title": "Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T Acute Lymphoblastic Leukemia",
        "T Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 160,
      "start_date": "2007-07-11",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00501826"
    },
    {
      "nct_id": "NCT06697184",
      "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "CLL",
        "Mantle Cell Lymphoma",
        "MCL"
      ],
      "interventions": [
        {
          "name": "Sonrotoclax",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2025-01-23",
      "completion_date": "2032-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Fort Wayne, Indiana • Westwood, Kansas + 3 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06697184"
    },
    {
      "nct_id": "NCT00719147",
      "title": "AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Avascular Necrosis",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Functional Status and Symptom Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 170,
      "start_date": "2001-07",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2011-09-27",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00719147"
    },
    {
      "nct_id": "NCT04149821",
      "title": "Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "CLL Progression",
        "CLL/SLL"
      ],
      "interventions": [
        {
          "name": "Umbralisib",
          "type": "DRUG"
        },
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-02-10",
      "completion_date": "2022-06-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04149821"
    },
    {
      "nct_id": "NCT00006221",
      "title": "BMS-247550 in Treating Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 3,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006221"
    },
    {
      "nct_id": "NCT04639843",
      "title": "Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult T-cell Leukemia/Lymphoma",
        "Extranodal NK-/T-cell Lymphoma, Nasal Type",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma",
        "Hepatosplenic T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CC-486 (5-azacitidine)",
          "type": "DRUG"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-11-03",
      "completion_date": "2022-11-03",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-11-14T20:12:19.359Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639843"
    }
  ]
}